ObjectiveTo study the dynamic express of CD57 on T cell of PBMC and clinical significance in acute HIV infection.MethodsSeventeen patients with acute HIV infection were enrolled study randomly diagnosed from 2006.11 to 2009.12 and 15 healthy donors as control group.The PBMCs from 1th,3th and 6th during acute infection were collected.The proportion of CD3+CD57+T lymphocytes,CD3+ CD8+CD57 +T lymphocytes and CD3 + CD4 + CD57 + T lymphocytes were evaluated by flow cytometric analysis with three or double color staining.The relationship between the proportion of CD57+ T phenotypes and virus load and CD4+T cells count was analyzed.ResultsThe proportion of CD57+T lymphocytes in PMBC in 1th,3th and 6th during acute HIV acute was 15.24％ ±1.49％,13.51％ ±2.45％ and 14.65％ ±1.83％,respectively,and was higher than normal control group and the difference was significantly(P＜0.0001 ).The proportion of CD8+ CD57+T lymphocytes was 7.79％ ±2.10％ and 9.88％ ±2.36％ in 1th and 3th month during acute infection,respectively.The proportion of CD8+ CD57+T lymphocytes in 1th and 3th month during acute infection were positive relationship with virus load in corresponding time,and R2 was 0.3700 and 0.3768,and P value was 0.0096 and 0.0088,respectively.The proportion of CD8+CD57+T lymphocytes in the 1th and 3th month during acute infection was negative relationship with CD4+T lymphocytes count.The R2 was 0.3768 and 0.4235,and P value was 0.0215 and 0.0017,respectively.In 6 rapid progressors and 11 no rapid progressors on the 1th month after HIV infection,CD8+ CD57+T lymphocytes percentage was 11.20％±2.21％ and 6.16％ ±1.09％,respectively,and CD4+CD57+T lymphocytes percentage 2.79％ ±0.31％and 1.40％ ±0.30％,respectively.Both CD8+CD57+T and CD4+CD57+T in rapid progressors were higher than no rapid progressors,and P value was 0.0338 and 0.0106,respectively.ConclusionCD57+ T lymphocytes percentage in peripheral blood increase in acute HIV infection patients,in which the increasing CD8+CD57+T lymphocyte may mirror the dynamic of HIV replication and CD4+T cell count.The CD57 high express on T lymphocyte on the early HIV acute infection predicts rapid progression.

Objective Evaluate the clinical value of nerve growth factor (NGF) in patients with interstitial cystitis for diagnosis and predicting the prognostic.Methods From January 2013 to January 2017,22 cases of interstitial cystitis patients,including 20 female cases and 2 male cases,were collected.Their mean age was (48.5 ± 12.8) years old.The average frequency of urination was 25.4 ±4.6 before treatment.The average frequency of nocturia was 4.6 ± 0.5.The average maximal bladder volume was (223.4 ± 39.5)ml.Their IPSS and QOL scores were 17.3 ± 1.2,12.7 ± 1.7,respectively.Meanwhile,22 healthy volunteers,including 18 female cases and 4 male cases,were collected.Their mean age was (40.2 ± 8.7) years old.The average frequency of urination was 4.2 ± 2.6 before treatment.The average frequency of nocturia was 1.1 ± 0.4.Urine NGF of these patients were collected before and after sodium hyaluronate bladder perfusion treatment,and the levels of NGF were detected by ELISA method.The correlationship between NGF and the severity of the symptoms were evaluated before and after treatment.Results After 1,3 and 6 months' treatment,the levels of NGF were dropped from (243.5 ±37.8) ng/L to (187.3 ±28.7) ng/L,(141.5 ± 21.3) ng/L and (123.1 ± 15.9) ng/L,which was positively associated with the degree of clinical symptom.The number of urination droppted from 25.4 ± 4.6 to 21.7 ± 5.2,17.2 ± 3.9 and 14.6 ± 3.8.The number of nocturia was dropped from 4.6 ± 0.5 to 3.8 ± 0.6,3.0 ± 0.8 and 1.7 ± 1.1.The maximum volume of bladder increased from (223.4 ± 39.5) ml to (258.7 ± 40.2) ml,(289.6 ± 37.1) ml and (305.2±40.4) ml.The IPSS scores dropped from 17.3 ± 1.2 to 15.1 ±2.4,12.4 ± 1.82and 9.8 ± 1.4.The QOL scores dropped from 12.7 ± 1.7 to 10.6 ± 1.2,8.5 ± 1.5 and 7.1 ± 1.3 (P ＜ 0.05).The logistic regression analysis showed the level of NGF in IC patients has positive relationship with frequency of urination,nocturia,QOL scores,IPSS scores and maximal bladder volume (P ＜ 0.05).Conclusions The level of NGF in urine is associated with IC symptom severity and NGF has the potential to be used as a marker for the diagnosis of IC.

Objective To establish a quantitative assay of serum Golgi protein 73 ( GP73) using xMAP technology and evaluate its performance. Methods Monoclonal antibodies against GP73 were prepared and purified, and antibody pair screening was performed by double?antibody sandwich enzyme?linked immunosorbent assay. The screened antibodies were used to construct a Luminex liquid chip detection system, and the analysis performance of the detection system was evaluated. The serum levels of GP73 were detected in 90 clinical samples from healthy controls and patients with chronic hepatitis B infection ( CHB) and hepatocellular carcinoma ( HCC). Results Five anti?GP73 monoclonal antibodies were prepared and purified, and 5 antibody pairs were successfully screened.The Luminex liquid chip detection system of GP73 was successfully constructed using 8F10D1 and 10B9F11 antibody pairs. The analytical performance evaluation showed that the sensitivity of this system was 0.25 ng／ml and the dynamic range was 0.25?100 ng／ml. No cross reactivity was observed. The intra? and inter?assay variation for GP73 was ＜8% and ＜11%, respectively. The recovery was 83%?92%. The linear regression equation was y＝1.141x+6.436 ( r2 ＝0.998 4, P＜0.001). The GP73 concentrations in the serum samples of healthy control, CHB group, and HCC group were 42.8 (38.68, 55.90) ng／ml, 61.49 (43.59, 81) ng／ml, and 122.78 (49.36 liter, 264.55) ng／ml, respectively.The levels of GP73 in HCC group were significantly higher than those in CHB group and healthy controls (P＜0.05). Moreover, the levels of GP73 in CHB group were significantly higher than those in healthy controls ( P＜0.05). Conclusions A liquid chip detection system of GP73 was successfully constructed. It provides a powerful tool for the clinical application of GP73 in the future.

Objective To establish a quantitative assay of serum Golgi protein 73 ( GP73) using xMAP technology and evaluate its performance. Methods Monoclonal antibodies against GP73 were prepared and purified, and antibody pair screening was performed by double?antibody sandwich enzyme?linked immunosorbent assay. The screened antibodies were used to construct a Luminex liquid chip detection system, and the analysis performance of the detection system was evaluated. The serum levels of GP73 were detected in 90 clinical samples from healthy controls and patients with chronic hepatitis B infection ( CHB) and hepatocellular carcinoma ( HCC). Results Five anti?GP73 monoclonal antibodies were prepared and purified, and 5 antibody pairs were successfully screened.The Luminex liquid chip detection system of GP73 was successfully constructed using 8F10D1 and 10B9F11 antibody pairs. The analytical performance evaluation showed that the sensitivity of this system was 0.25 ng／ml and the dynamic range was 0.25?100 ng／ml. No cross reactivity was observed. The intra? and inter?assay variation for GP73 was ＜8% and ＜11%, respectively. The recovery was 83%?92%. The linear regression equation was y＝1.141x+6.436 ( r2 ＝0.998 4, P＜0.001). The GP73 concentrations in the serum samples of healthy control, CHB group, and HCC group were 42.8 (38.68, 55.90) ng／ml, 61.49 (43.59, 81) ng／ml, and 122.78 (49.36 liter, 264.55) ng／ml, respectively.The levels of GP73 in HCC group were significantly higher than those in CHB group and healthy controls (P＜0.05). Moreover, the levels of GP73 in CHB group were significantly higher than those in healthy controls ( P＜0.05). Conclusions A liquid chip detection system of GP73 was successfully constructed. It provides a powerful tool for the clinical application of GP73 in the future.

Objective: To establish a quantitative assay of serum Golgi protein 73 (GP73) using xMAP technology and evaluate its performance. Methods: Monoclonal antibodies against GP73 were prepared and purified, and antibody pair screening was performed by double-antibody sandwich enzyme-linked immunosorbent assay. The screened antibodies were used to construct a Luminex liquid chip detection system, and the analysis performance of the detection system was evaluated. The serum levels of GP73 were detected in 90 clinical samples from healthy controls and patients with chronic hepatitis B infection (CHB) and hepatocellular carcinoma (HCC). Results: Five anti-GP73 monoclonal antibodies were prepared and purified, and 5 antibody pairs were successfully screened. The Luminex liquid chip detection system of GP73 was successfully constructed using 8F10D1 and 10B9F11 antibody pairs. The analytical performance evaluation showed that the sensitivity of this system was 0.25 ng/ml and the dynamic range was 0.25-100 ng/ml. No cross reactivity was observed. The intra- and inter-assay variation for GP73 was <8% and <11%, respectively. The recovery was 83%-92%. The linear regression equation was y=1.141x+ 6.436 (r²=0.998 4, P<0.001). The GP73 concentrations in the serum samples of healthy control, CHB group, and HCC group were 42.8 (38.68, 55.90) ng/ml, 61.49 (43.59, 81) ng/ml, and 122.78 (49.36 liter, 264.55) ng/ml, respectively. The levels of GP73 in HCC group were significantly higher than those in CHB group and healthy controls (P<0.05). Moreover, the levels of GP73 in CHB group were significantly higher than those in healthy controls (P<0.05). Conclusions A liquid chip detection system of GP73 was successfully constructed. It provides a powerful tool for the clinical application of GP73 in the future.

Patients with severe trauma require an extremely timely treatment and transfusion plays an irreplaceable role in the emergency treatment of such patients. An increasing number of evidence-based medicinal evidences and clinical practices suggest that patients with severe traumatic bleeding benefit from early transfusion of low-titer group O whole blood or hemostatic resuscitation with red blood cells, plasma and platelet of a balanced ratio. However, the current domestic mode of blood supply cannot fully meet the requirements of timely and effective blood transfusion for emergency treatment of patients with severe trauma in clinical practice. In order to solve the key problems in blood supply and blood transfusion strategies for emergency treatment of severe trauma, Branch of Clinical Transfusion Medicine of Chinese Medical Association, Group for Trauma Emergency Care and Multiple Injuries of Trauma Branch of Chinese Medical Association, Young Scholar Group of Disaster Medicine Branch of Chinese Medical Association organized domestic experts of blood transfusion medicine and trauma treatment to jointly formulate Chinese expert consensus on blood support mode and blood transfusion strategies for emergency treatment of severe trauma patients ( version 2024). Based on the evidence-based medical evidence and Delphi method of expert consultation and voting, 10 recommendations were put forward from two aspects of blood support mode and transfusion strategies, aiming to provide a reference for transfusion resuscitation in the emergency treatment of severe trauma and further improve the success rate of treatment of patients with severe trauma.